# Moderna

> Moderna is a Cambridge, Massachusetts biotechnology company built on a single idea: that messenger RNA can be used as software to instruct the body to make its own medicines. Founded in 2010, it spent a decade with no approved product before its COVID-19 vaccine reached hundreds of millions of arms. Today it sells three commercial vaccines, runs a pipeline that stretches from seasonal flu to personalized cancer therapies, and treats mRNA less as a product than as a manufacturing platform - one where the code changes but the factory stays the same.

- **Founded:** 2010
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Noubar Afeyan (Co-founder & Chairman (Flagship Pioneering)), Derrick Rossi (Co-founder (scientific)), Robert Langer (Co-founder (scientific, MIT)), Kenneth Chien (Co-founder (scientific)), Stephane Bancel (Chief Executive Officer (joined 2011))
- **Team size:** ~4,700-4,800 employees
- **Products:** Spikevax, mNEXSPIKE, mRESVIA, mRNA-1010 (seasonal flu), Intismeran autogene (mRNA-4157/V940)
- **Notable:** Co-developed one of the first authorized mRNA COVID-19 vaccines (mRNA-1273), reaching hundreds of millions of people worldwide., Designed its COVID-19 vaccine candidate in roughly two days from a digital gene sequence and reached first-in-human trials in about 63 days., Grew from zero approved products to three commercial vaccines (Spikevax, mRESVIA, mNEXSPIKE).

## Products & services

- **Spikevax** — Moderna's original mRNA COVID-19 vaccine (mRNA-1273), first authorized in the U.S. in December 2020. In July 2025 the FDA approved Spikevax for children six months through 11 years at increased risk of COVID-19.
- **mNEXSPIKE** — Next-generation, lower-dose mRNA COVID-19 vaccine approved by the FDA in May 2025 for adults 65+ and people 12-64 with at least one risk factor.
- **mRESVIA** — mRNA vaccine against respiratory syncytial virus (RSV); indication expanded in June 2025 to include at-risk adults 18-59 in addition to adults 60+.
- **mRNA-1010 (seasonal flu)** — Seasonal influenza vaccine that reported Phase 3 efficacy and safety data in 2025; Moderna targeted regulatory submissions in the U.S., Canada, Australia and Europe.
- **Intismeran autogene (mRNA-4157/V940)** — Individualized neoantigen therapy - a personalized cancer vaccine developed with Merck, designed from a patient's own tumor mutations. In melanoma (with Keytruda), five-year data showed a 49% reduction in risk of recurrence or death versus Keytruda alone.
- **mRNA therapeutics pipeline** — Investigational programs across rare genetic diseases, latent and other infectious diseases (CMV, norovirus), and combination respiratory vaccines - all built on the same mRNA platform.

## Achievements

- Co-developed one of the first authorized mRNA COVID-19 vaccines (mRNA-1273), reaching hundreds of millions of people worldwide.
- Designed its COVID-19 vaccine candidate in roughly two days from a digital gene sequence and reached first-in-human trials in about 63 days.
- Grew from zero approved products to three commercial vaccines (Spikevax, mRESVIA, mNEXSPIKE).
- Five-year melanoma data for its personalized cancer vaccine (with Merck) showed a sustained 49% reduction in risk of recurrence or death versus Keytruda alone.
- Completed one of the largest IPOs in biotech history in December 2018.

## Latest updates

- **2026-01** — Moderna and Merck reported five-year follow-up data for intismeran autogene plus Keytruda, showing a sustained 49% reduction in recurrence-or-death risk in high-risk resected melanoma.
- **2025-10** — Moderna presented Phase 3 efficacy and safety data for its seasonal flu vaccine (mRNA-1010) and targeted regulatory submissions in the U.S., Canada, Australia and Europe by January 2026.
- **2025-07** — FDA approved Spikevax for children six months through 11 years at increased risk of COVID-19.
- **2025-06** — FDA expanded mRESVIA to at-risk adults aged 18-59, adding to the existing 60+ indication.
- **2025-05** — FDA approved mNEXSPIKE, Moderna's next-generation COVID-19 vaccine, for adults 65+ and at-risk people 12-64.

## Links

- Website: https://www.modernatx.com
- LinkedIn: https://www.linkedin.com/company/modernatx
- Twitter/X: https://twitter.com/moderna_tx
- YouTube: https://www.youtube.com/modernatx
- Instagram: https://www.instagram.com/moderna_tx/
- Facebook: https://www.facebook.com/modernatx

---

Profile page: https://yespress.io/moderna
Published by YesPress — https://yespress.io
Last updated: 2026-08-13